CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
Ipilimumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01585194
NCT01585194Phase 2Completed
CompareCT.gov

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

M.D. Anderson Cancer Center·interventional·Posted Apr 25, 2012·Updated Jul 9, 2024

In Brief

A Phase 2 clinical trial evaluating Ipilimumab, Laboratory Biomarker Analysis, and 1 other intervention for Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7. Completed, enrolled 67 participants across 1 site.

Detailed Summary

This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2012
Enrollment StartNov 29, 2012
Primary CompletionDec 2, 2019
Study CompletionMay 14, 2024
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 14.2 years ago

Interventions

Ipilimumabbiological

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Nivolumabbiological

Given IV